Knight Therapeutics Secures US$38.5 Million Loan from IFC for Latin America

Knight Therapeutics Inc., a specialty pharmaceutical company operating across the Pan-American region excluding the USA, has secured a five-year, US$38.5 million secured loan denominated in select Latin American currencies with the International Finance Corporation (IFC). The funding is intended to support Knight's business development and expansion initiatives within Latin American markets.

The IFC, a member of the World Bank Group, focuses on strengthening the private sector in emerging economies. This loan signifies their commitment to supporting Knight Therapeutics in its mission to improve access to significant new and differentiated medicines in the region. The financing is expected to bolster Knight's strategic objective of addressing unmet medical needs across Latin America.

This financial development follows a series of recent strategic moves by Knight Therapeutics. The company recently announced the relaunch of AKYNZEO® (netupitant/palonosetron capsules) in Canada and has submitted a marketing authorization application for tafasitamab in Brazil. These actions underscore Knight's ongoing efforts to broaden its product portfolio and market reach.

Knight Therapeutics also reported robust financial results for the third quarter of 2022, achieving record revenues and adjusted EBITDA for the first nine months of the year. This financial strength provides a solid foundation for the company's continued growth and strategic advancements throughout the Americas.